Ma Y Y, Zhang J J, Gao X M
Department of Orthodontics, Peking University School and Hospital of Stomatology & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2017 Aug 18;49(4):691-698.
To evaluate the polysomnology results along with mandibular titrated advancement using oral appliance to treat obstructive sleep apnea and hyponea syndrome (OSAHS).
Several electronic databases (PubMed, Embase, Cochrane Library, CNKI, VIP, and Wanfang) were systematically searched up to September 2015. There was no restriction of language or source of information. All randomized clinical trials (RCT) and before-after trials (BAT) comparing at least two different mandibular advancements were included. Two independent reviewers selected the studies, extracted data and evaluated risk of bias by quality assessment. Data were pooled using a fixed-effects model, and the summary effect measure was calculated by risk ratio (RR) and 95%CI. Meta-analysis was performed using RevMan 5.3 software.
Two RCTs and five BATs were included in the review. Among the five BATs, two of them were randomized, while the other three were not. Outcomes including apnea hypopnea index (AHI), oxygen desaturation index (ODI), success rate (reduction of AHI or ODI >50%), normalization rate (AHI or ODI<10/h) were assessed in this review. Based on the trial design and quality assessment, four studies were included for meta-analysis. No significant difference in the success rate was found between the group with 50% of the maximal mandibular advancement (MMA) and the group with 75% of MMA [I=0%, RR=0.93, with 95%CI (0.80, 1.09)]. No significant difference in the normalization rate was found between the 50% of MMA and 75% of MMA groups [I=45%, RR=0.85, with 95%CI (0.68, 1.06)]. Subgroup analysis displayed that the severity of OSAHS before treatment was a potential factor affecting the normalization rate.
Based on current available evidence, the success rate and normalization rate for treating OSAHS in the patients with 75% MMA were not found to be significantly higher than those with 50% MMA. Due to small simple size in this meta-analysis, the results of the present study should be interpreted with caution. Further prospective studies are needed to strengthen the evidence.
评估多导睡眠图结果以及使用口腔矫治器进行下颌滴定前移治疗阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的情况。
系统检索截至2015年9月的多个电子数据库(PubMed、Embase、Cochrane图书馆、中国知网、维普和万方)。对语言或信息来源无限制。纳入所有比较至少两种不同下颌前移的随机临床试验(RCT)和前后试验(BAT)。两名独立的评审员选择研究、提取数据并通过质量评估评估偏倚风险。使用固定效应模型合并数据,并通过风险比(RR)和95%置信区间计算汇总效应量。使用RevMan 5.3软件进行荟萃分析。
该综述纳入了两项RCT和五项BAT。在五项BAT中,其中两项是随机的,另外三项不是。本综述评估了包括呼吸暂停低通气指数(AHI)、氧饱和度下降指数(ODI)、成功率(AHI或ODI降低>50%)、正常化率(AHI或ODI<10/h)等结果。基于试验设计和质量评估,纳入四项研究进行荟萃分析。最大下颌前移(MMA)50%的组与MMA 75%的组在成功率方面未发现显著差异[I=0%,RR=0.93,95%置信区间(0.80,1.09)]。MMA 50%的组与MMA 75%的组在正常化率方面未发现显著差异[I=45%,RR=0.85,95%置信区间(0.68,1.06)]。亚组分析显示,治疗前OSAHS的严重程度是影响正常化率的一个潜在因素。
基于现有证据,未发现MMA 75%的患者治疗OSAHS的成功率和正常化率显著高于MMA 50%的患者。由于本荟萃分析的样本量较小,本研究结果应谨慎解释。需要进一步的前瞻性研究来加强证据。